Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical volume of 165 put options. Get Xenon Pharmaceuticals alerts: Xenon Pharmaceuticals Stock Performance Xenon 129
Shares of NASDAQ XENE opened at $38.59 on Thursday. The company's fifty day moving average price is $38.31 and its 200 day moving average price is $38.31. Xenon Pharmaceuticals has a 1 year low of $31.79 and a 1 year high of $43.75. The company has a market capitalization of $2.48 billion, a PE ratio of -15.61 and a beta of 1.39.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). During the same period in the previous year, the firm earned ($0.55) EPS. Xenon Pharmaceuticals's revenue for the quarter was down 100.0% compared to the same quarter last year. On average, equities analysts expect that Xenon Pharmaceuticals will post -2.89 EPS for the current year. Insider Buying and Selling at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, Director Simon N. Pimstone sold 62,526 shares of the business's stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $38.70, for a total value of $2,419,756.20. Following the completion of the sale, the director now directly owns 6,000 shares of the company's stock, valued at approximately $232,200. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.43% of the stock is owned by corporate insiders. Hedge Funds Weigh In On Xenon Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its holdings in Xenon Pharmaceuticals by 7.7% during the second quarter. California State Teachers Retirement System now owns 44,375 shares of the biopharmaceutical company's stock valued at $1,708,000 after purchasing an additional 3,167 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Xenon Pharmaceuticals by 294.6% in the second quarter. Osaic Holdings Inc. now owns 2,691 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,009 shares in the last quarter. Legato Capital Management LLC purchased a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $474,000. Castleark Management LLC lifted its stake in shares of Xenon Pharmaceuticals by 21.5% in the second quarter. Castleark Management LLC now owns 94,490 shares of the biopharmaceutical company's stock worth $3,638,000 after buying an additional 16,750 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Xenon Pharmaceuticals by 1,384.9% in the second quarter. Wells Fargo & Company MN now owns 58,593 shares of the biopharmaceutical company's stock worth $2,256,000 after buying an additional 54,647 shares in the last quarter. 90.75% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth
A number of research firms recently commented on XENE. Wedbush reissued an "outperform" rating and set a $47.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, August 10th. Cantor Fitzgerald reissued an "overweight" rating and set a $58.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, August 10th. Stifel Nicolaus increased their target price on shares of Xenon Pharmaceuticals from $52.00 to $53.00 in a research report on Wednesday, May 10th. Finally, StockNews.com began coverage on shares of Xenon Pharmaceuticals in a research note on Thursday, August 17th. They set a "sell" rating on the stock. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $51.73.
Read Our Latest Stock Analysis on Xenon PharmaceuticalsAbout Xenon Pharmaceuticals (Get Free Report)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.Further ReadingFive stocks we like better than Xenon PharmaceuticalsHow Can Investors Use the Dogs of the Dow Strategy?Bear Market vs Recession: What Are the Differences?Best ESG Stocks: 11 Best Stocks for ESG Investing7 Best AI Mutual Funds (and ETFs) to Sweep the AI Craze What is the Dow Jones Industrial Average (DJIA)?Auto Parts Stocks Shift Gears: Which is the Right One to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
326 E 8th St #105, Sioux Falls, SD 57103 contact@marketbeat.com (844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
Laser Gas Argon © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.